Combination therapy for treating HER2-positive cancers

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9913901
SERIAL NO

14650250

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MERRIMACK PHARMACEUTICALS INCONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Espelin, Christopher W Belmont, US 3 0
Geretti, Elena Cambridge, US 15 11
Hendriks, Bart S Belmont, US 21 72
Moyo, Victor Ringoes, US 42 244
Reynolds, Joseph G North Andover, US 9 5
Wickham, Thomas Groton, US 27 135

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 13, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 13, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00